DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

CPVT. See Catecholaminergic
polymorphic ventricular
tachycardia (CPVT)
Cranial nerves, 171, 173f
Cranial nerve visceral sensory system,
171
C-reactive protein, statins and, 895
Cream(s), 1807t
Creatinine clearance, 1803
CRESTOR (rosuvastatin), 897
Cretinism, 1140
Creutzfeldt-Jakob disease, from
contaminated growth
hormone, 5
Crigler-Najjar syndrome type I, 133,
151
Crigler-Najjar syndrome type II, 133
CRINONE (micronized progesterone),
1844
CRIXIVAN (indinavir), 1626t
Crohn’s disease, biological agents for,
1825t
Cromolyn sodium, for ophthalmic use,
1789
Crotamiton, 1819
CRTh2 antagonists, 1055
Cryptosporidiosis, 1421
CSA. See Controlled Substances Act
(CSA)
CSF. See Cerebrospinal fluid (CSF)
CTCL. See Cutaneous T-cell
lymphoma (CTCL)
CTOP, actions and selectivities of, 485t
C-type natriuretic peptide (CNP),
695–696
Cul-de-sac, inferior (ocular), 1773
Curare. See also Neuromuscular
blocking agents
action of, 258
ancient use of, 3
Cutaneous administration of drugs,
1803, 1804f
absorption mechanisms in,
1804–1805
Cutaneous T-cell lymphoma (CTCL)
alkylating agents for, 1821
denileukin diftitox for, 1827
methotrexate for, 1820
photochemotherapy for, 1814–1815,
1814t
retinoids for, 1811–1812, 1811t
vinblastine for, 1823
Cyanide antidote, 86t
Cyanoacrylate tissue adhesive, ocular
use, 1790
CYCLESSA (ethinyl
estradiol/desogestrel), 1835t
Cyclic AMP, 55–56
Cyclic AMP-regulated guanine
nucleotide exchange factors
(GEFs), 56
Cyclic GMP, 63–65
Cyclizine hydrochloride, 921t, 924
Cyclizine lactate, 921t
Cyclobenzaprine, pharmacokinetics of,
1828t
CYCLOCORT (amcinonide), 1225t
CYCLOGYL (cyclopentolate), 1788
CYCLOMYDRIL, 1788
Cyclooxygenase, products of, 939
Cyclooxygenase-1 (COX-1), 938f, 939,
959–960
aspirin and, 964
inhibitors, 941–942
NSAIDs and, 959
Cyclooxygenase-2 (COX-2), 938f, 939,
959–960, 962
aspirin and, 964
inhibitors, 941–942, 964–965
NSAIDs and, 959
Cyclooxygenase (COX), COX-1, 868
Cyclooxygenase (COX) inhibitors,
868, 937
COX-2, 962f
classification of, 970t
structure of, 963f
for prevention of preterm labor,
1848
Cyclopentolate hydrochloride, 233
Cyclophosphamide, 994t, 1668t–1670t
adverse effects and side effects of,
1821
in dermatology, 1821
dosage and administration of, 1821
FDA-approved indications for, 1821
mechanism of action of, 1820t
pharmacokinetics of, 1828t
polymorphisms and response to, 159t
toxicity of, extramedullary, 1682t
and vasopressin secretion, 704
Cycloplegia, 228, 233
autonomic agents for, 1785t
Cycloserine, 1562–1563
Cycloserine, SLC transporters and,
103t
Cyclosporin A, cerivastatin and, 110
Cyclosporine, 994t
ABC transporters and, 105t
adverse effects and side effects of,
1821
Cyclosporine (Cont.):
drug interactions with, 839
in immunosuppressive therapy,
1009–1012
for inflammatory bowel disease,
1358–1359
mechanism of action of, 1820t, 1821
metabolism of, 128t
monitoring, 1821
for ophthalmic use, 1790
pharmacokinetics of, 1829t
polymorphisms and response to,
159t
for psoriasis, 1821
and statins, interactions, 896
therapeutic uses of, for
inflammatory bowel disease,
1352t
toxicity of, 1821
CYKLOKAPRON (tranexamic acid),
867–868
Cyanocobalamin. See Vitamin B 12
CYP3A4
ABC transporters and, 104
inhibition, 1650
polymorphisms, 159t
rectal administration and, 21
CYP3A5, polymorphisms of, 156, 158f
CYP2B6, 159t
CYP2C9, 157–158, 159t, 162f
CYP2C9
genotype/haplotype, effects on
warfarin, 862–863, 863t, 864
genotype/haplotype frequencies, in
different populations, 863t
CYP2C19, 157, 159t, 161f
CYP2C19, polymorphisms
and clopidogrel, 870
and prasugrel, 869f, 870
CYP2D6, 156–157, 159t
Cyproheptadine, 351, 921t, 924
pharmacokinetics of, 1816t
Cyproterone acetate, 1205, 1765
structure of, 1761f
CYPs, 127–130
Cystathionine beta-synthase, 148
Cysteine conjugates, 102t
Cystic fibrosis, ABC transporters and,
104t
Cystinuria, SLC transporters and, 102t
Cytarabine, 1668t–1670t, 1698–1700
pharmacokinetics of, 1829t
Cytidine analogs, 1698–1701
Cytisim, cholinergic receptors and,
206t
2015
INDEX